You are not currently logged in.
Access JSTOR through your library or other institution:
If You Use a Screen ReaderThis content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Chloramphenicol versus Ampicillin Plus Gentamicin for Community Acquired Very Severe Pneumonia among Children Aged 2-59 Months in Low Resource Settings: Multicentre Randomised Controlled Trial (SPEAR Study)
Rai Asghar, Salem Banajeh, Josefina Egas, Patricia Hibberd, Imran Iqbal, Mary Katep-Bwalya, Zafarullah Kundi, Paul Law, William MacLeod, Irene Maulen-Radovan, Greta Mino, Samir Saha, Fernando Sempertegui, Jonathon Simon, Mathuram Santosham, Sunit Singhi, Donald M. Thea, Shamim Qazi and Bhutta
BMJ: British Medical Journal
Vol. 336, No. 7635 (Jan. 12, 2008), pp. 80-84
Published by: BMJ
Stable URL: http://www.jstor.org/stable/20508665
Page Count: 5
You can always find the topics here!Topics: Children, Medical treatment failures, Pneumonia, Health outcomes, Bacterial pneumonia, Antibiotics, Teaching hospitals, Public health, Streptococcus pneumoniae, Mortality
Were these topics helpful?See something inaccurate? Let us know!
Select the topics that are inaccurate.
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
Objective: To evaluate whether five days' treatment with injectable ampicillin plus gentamicin compared with chloramphenicol reduces treatment failure in children aged 2-59 months with community acquired very severe pneumonia in low resource settings. Design: Open label randomised controlled trial. Setting: Inpatient wards within tertiary care hospitals in Bangladesh, Ecuador, India, Mexico, Pakistan, Yemen, and Zambia. Participants: Children aged 2-59 months with WHO defined very severe pneumonia. Intervention: Chloramphenicol versus a combination of ampicillin plus gentamicin. Main outcome measures: Primary outcome measure was treatment failure at five days. Secondary outcomes were treatment failure defined similarly among all participants evaluated at 48 hours and at 10 and 21 days. Results: More children failed treatment with chloramphenicol at day 5 (16% v 11%; relative risk 1.43, 95% confidence interval 1.03 to 1.97) and also by days 10 and 21. Overall, 112 bacterial isolates were obtained from blood and lung aspirates in 110 children (11.5%), with the most common organisms being Staphylococcus aureus (n=47) and Streptococcus pneumoniae (n=22). In subgroup analysis, bacteraemia with any organism increased the risk of treatment failure at 21 days in the chloramphenicol group (2.09, 1.41 to 3.10) but not in the ampicillin plus gentamicin group (1.12, 0.59 to 2.13). Similarly, isolation of S pneumoniae increased the risk of treatment failure at day 21 (4.06, 2.73 to 6.03) and death (5.80, 2.62 to 12.85) in the chloramphenicol group but not in the ampicillin plus gentamicin group. No difference was found in treatment failure for children with S aureus bacteraemia in the two groups, but the power to detect a difference in this subgroup analysis was low. Independent predictors of treatment failure by multivariate analysis were hypoxaemia (oxygen saturation <90%), receiving chloramphenicol, being female, and poor immunisation status. Conclusion: Injectable ampicillin plus gentamicin is superior to injectable chloramphenicol for the treatment of community acquired very severe pneumonia in children aged 2-59 months in low resource settings. Trial registration: Current Controlled Trials ISRCTN39543942.
BMJ: British Medical Journal © 2008 BMJ